Clinical trials
Phase 2 Stomach Neoplasms trials in the Netherlands
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
17 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2015 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 6 |
| Recruiting | 4 |
| Active, not recruiting | 3 |
| Terminated | 2 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| The Netherlands Cancer Institute | 3 |
| Erasmus Medical Center | 2 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 1 |
| AstraZeneca | 1 |
| Blue Earth Diagnostics | 1 |
| Daiichi Sankyo | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| Hoffmann-La Roche | 1 |
| Jeroen Bosch Ziekenhuis | 1 |
| Merck Sharp & Dohme LLC | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Stomach Neoplasms | 17 |
| Esophageal Neoplasms | 4 |
| Breast Neoplasms | 2 |
| Carcinoma, Hepatocellular | 2 |
| Colorectal Neoplasms | 2 |
| Endometrial Neoplasms | 2 |
| Lung Neoplasms | 2 |
| Ovarian Neoplasms | 2 |
| Urinary Bladder Neoplasms | 2 |
| Uterine Cervical Neoplasms | 2 |
Trials
Showing 1 to 17 of 17. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.